PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31618764-7	2019	Of those, the heterozygous variant exon11:c.2299C>T: p.Arg767Cys in OAS3, a gene used to synthesize 2"-5"-oligoadenylate (2-5A), co-segregates with the disease phenotype.	2',5'-oligoadenylate	100-120	2'-5'-oligoadenylate synthetase 3	Homo sapiens	68-72
30655338-4	2019	Here, we developed a biosensor for 2",5"-oligoadenylate (2-5A), the natural activator of RNase L.	2',5'-oligoadenylate	35-55	ribonuclease L	Homo sapiens	89-96
31933969-9	2019	Subsequently, we demonstrated that upregulation of miR-221 promoted the expression of representative interferon stimulated genes (ISGs) such as myxovirus protein A (MxA), 2",5"-oligoadenylate synthetases (OAS) and murine IFN-stimulated gene 15 (ISG15).	2',5'-oligoadenylate	171-191	microRNA 221	Mus musculus	51-58
30655338-4	2019	Here, we developed a biosensor for 2",5"-oligoadenylate (2-5A), the natural activator of RNase L.	2',5'-oligoadenylate	57-61	ribonuclease L	Homo sapiens	89-96
27364610-4	2016	The doxifluridine-conjugated 8-methyladenosine-substituted 2-5A analog was significantly more effective as an activator of RNase L than the parent 5"-monophophorylated 2-5A tetramer and showed a tumor suppressive effect against human cervical cancer cells.	2',5'-oligoadenylate	59-63	ribonuclease L	Homo sapiens	123-130
30395302-6	2019	We propose the following model for the selective targeting of exogenous RNA; OAS3 activated by the exogenous RNA releases 2"-5"-oligoadenylates (2-5A), which in turn converts latent RNase L to an active dimer.	2',5'-oligoadenylate	122-143	2'-5'-oligoadenylate synthetase 3	Homo sapiens	77-81
30395302-6	2019	We propose the following model for the selective targeting of exogenous RNA; OAS3 activated by the exogenous RNA releases 2"-5"-oligoadenylates (2-5A), which in turn converts latent RNase L to an active dimer.	2',5'-oligoadenylate	122-143	ribonuclease L	Homo sapiens	182-189
27663720-2	2016	The OAS protein binds dsRNA and is activated to produce 2",5"-oligoadenylates, which lead to the activation of latent form of RNase L, resulting in degradation of cellular and viral RNA and inhibition of viral replication.	2',5'-oligoadenylate	62-77	ribonuclease L (2', 5'-oligoisoadenylate synthetase-dependent)	Mus musculus	126-133
26397719-5	2015	T-oligos injected into the uteri of pregnant CD1 mice on day 14 of gestation, led to increased p38MAPK, SA-beta-gal (SA beta-gal) staining in murine amniotic sacs and higher AF IL-8 levels on day 18, compared to saline treated controls.	2',5'-oligoadenylate	1-8	CD1 antigen complex	Mus musculus	45-48
27025250-6	2016	Here we report that MERS-CoV, a lineage CBetacoronavirus, and related bat CoV NS4b accessory proteins have phosphodiesterase (PDE) activity and antagonize OAS-RNase L by enzymatically degrading 2",5"-oligoadenylate (2-5A), activators of RNase L.	2',5'-oligoadenylate	194-214	ribonuclease L	Homo sapiens	159-166
27025250-6	2016	Here we report that MERS-CoV, a lineage CBetacoronavirus, and related bat CoV NS4b accessory proteins have phosphodiesterase (PDE) activity and antagonize OAS-RNase L by enzymatically degrading 2",5"-oligoadenylate (2-5A), activators of RNase L.	2',5'-oligoadenylate	194-214	ribonuclease L	Homo sapiens	237-244
26397719-5	2015	T-oligos injected into the uteri of pregnant CD1 mice on day 14 of gestation, led to increased p38MAPK, SA-beta-gal (SA beta-gal) staining in murine amniotic sacs and higher AF IL-8 levels on day 18, compared to saline treated controls.	2',5'-oligoadenylate	1-8	mitogen-activated protein kinase 14	Mus musculus	95-102
26397719-5	2015	T-oligos injected into the uteri of pregnant CD1 mice on day 14 of gestation, led to increased p38MAPK, SA-beta-gal (SA beta-gal) staining in murine amniotic sacs and higher AF IL-8 levels on day 18, compared to saline treated controls.	2',5'-oligoadenylate	1-8	C-X-C motif chemokine ligand 8	Homo sapiens	177-181
25892109-1	2015	2"-5"-Oligoadenylate synthetases (OASs) produce the second messenger 2"-5"-oligoadenylate, which activates RNase L to induce an intrinsic antiviral state.	2',5'-oligoadenylate	69-89	ribonuclease L	Homo sapiens	107-114
26055709-2	2015	OAS produces a unique oligonucleotide second messenger, 2",5"-oligoadenylate (2-5A), that binds and activates RNase-L.	2',5'-oligoadenylate	56-76	ribonuclease L	Homo sapiens	110-117
25878106-0	2015	Structural basis for 2"-5"-oligoadenylate binding and enzyme activity of a viral RNase L antagonist.	2',5'-oligoadenylate	21-41	ribonuclease L	Homo sapiens	81-88
25878106-1	2015	UNLABELLED: Synthesis of 2"-5"-oligoadenylates (2-5A) by oligoadenylate synthetase (OAS) is an important innate cellular response that limits viral replication by activating the latent cellular RNase, RNase L, to degrade single-stranded RNA.	2',5'-oligoadenylate	25-46	ribonuclease L	Homo sapiens	201-208
25878106-10	2015	IMPORTANCE: The C-terminal domain (CTD) of rotavirus VP3 is a 2H phosphoesterase that cleaves 2"-5"-oligoadenylates (2-5A), potent activators of an important innate cellular antiviral pathway.	2',5'-oligoadenylate	100-115	VP3	Rotavirus A	53-56
24570368-1	2014	The interferon (IFN)-inducible antiviral state is mediated in part by the 2",5"-oligoadenylate (2-5A) synthetase (OAS)/RNase L system.	2',5'-oligoadenylate	74-94	ribonuclease L (2', 5'-oligoisoadenylate synthetase-dependent)	Mus musculus	119-126
25816776-3	2015	We report that virus activation of the NLRP3 inflammasome involves the 2",5"-oligoadenylate (2-5A) synthetase(OAS)/RNase L system, a component of the interferon-induced antiviral response that senses double-stranded RNA and activates endoribonuclease RNase L to cleave viral and cellular RNAs.	2',5'-oligoadenylate	71-91	NLR family pyrin domain containing 3	Homo sapiens	39-44
25816776-3	2015	We report that virus activation of the NLRP3 inflammasome involves the 2",5"-oligoadenylate (2-5A) synthetase(OAS)/RNase L system, a component of the interferon-induced antiviral response that senses double-stranded RNA and activates endoribonuclease RNase L to cleave viral and cellular RNAs.	2',5'-oligoadenylate	71-91	SPARC related modular calcium binding 1	Homo sapiens	110-113
25816776-3	2015	We report that virus activation of the NLRP3 inflammasome involves the 2",5"-oligoadenylate (2-5A) synthetase(OAS)/RNase L system, a component of the interferon-induced antiviral response that senses double-stranded RNA and activates endoribonuclease RNase L to cleave viral and cellular RNAs.	2',5'-oligoadenylate	71-91	ribonuclease L	Homo sapiens	115-122
25816776-3	2015	We report that virus activation of the NLRP3 inflammasome involves the 2",5"-oligoadenylate (2-5A) synthetase(OAS)/RNase L system, a component of the interferon-induced antiviral response that senses double-stranded RNA and activates endoribonuclease RNase L to cleave viral and cellular RNAs.	2',5'-oligoadenylate	71-91	ribonuclease L	Homo sapiens	251-258
25275129-0	2014	The 2"-5"-oligoadenylate synthetase 3 enzyme potently synthesizes the 2"-5"-oligoadenylates required for RNase L activation.	2',5'-oligoadenylate	70-91	2'-5'-oligoadenylate synthetase 3	Homo sapiens	4-37
25275129-0	2014	The 2"-5"-oligoadenylate synthetase 3 enzyme potently synthesizes the 2"-5"-oligoadenylates required for RNase L activation.	2',5'-oligoadenylate	70-91	ribonuclease L	Homo sapiens	105-112
25275129-10	2014	We provide compelling evidence that OAS3 can produce 2"-5"-oligoadenylates of sufficient length to activate RNase L.	2',5'-oligoadenylate	53-74	2'-5'-oligoadenylate synthetase 3	Homo sapiens	36-40
25275129-10	2014	We provide compelling evidence that OAS3 can produce 2"-5"-oligoadenylates of sufficient length to activate RNase L.	2',5'-oligoadenylate	53-74	ribonuclease L	Homo sapiens	108-115
24780566-1	2014	The interferon-inducible, 2",5"-oligoadenylate (2-5A)-dependent endoribonuclease, RNase L is a unique antiviral RNA-degrading enzyme involved in RNA-metabolism, translational regulation, stress-response besides its anticancer/tumor-suppressor and antibacterial functions.	2',5'-oligoadenylate	26-46	ribonuclease L (2', 5'-oligoisoadenylate synthetase-dependent)	Mus musculus	82-89
24509240-1	2014	RNase L is a cellular endoribonuclease that is activated by 2",5"-linked oligoadenylates (2-5A), which are unique and specific ligands synthesized by a family of interferon-inducible, dsRNA-activated enzymes named oligoadenylate synthetases.	2',5'-oligoadenylate	73-88	ribonuclease L	Homo sapiens	0-7
23810677-0	2013	Solid-phase synthesis of 5"-triphosphate 2"-5"-oligoadenylates analogs with 3"-O-biolabile groups and their evaluation as RNase L activators and antiviral drugs.	2',5'-oligoadenylate	47-62	ribonuclease L	Homo sapiens	122-129
23113544-1	2013	The endoribonuclease RNase-L is the terminal component of an interferon-regulated RNA decay pathway known as the 2"-5"-oligoadenylate (2-5A) system, whose established functions include antimicrobial and tumor suppressive activities.	2',5'-oligoadenylate	113-133	ribonuclease L	Homo sapiens	21-28
22497258-0	2012	Structure-activity relationships of 2",5"-oligoadenylate analogue modifications of prostate-specific membrane antigen (PSMA) antagonists.	2',5'-oligoadenylate	36-56	folate hydrolase 1	Homo sapiens	83-117
22542997-7	2012	The observed substrate specificity may refer to the specific role of the enzyme in the degradation of natural 2",5"-oligoadenylates (2-5A) that function in the interferon-induced mammalian 2-5A system as allosteric regulators of ribonuclease L.	2',5'-oligoadenylate	110-131	ribonuclease L	Homo sapiens	229-243
22875977-5	2012	Similarly, direct activation of RNase L with a 2",5"-oligoadenylate resulted in p62(SQSTM1) degradation, LC3BI/LC3BII conversion, and appearance of autophagosomes.	2',5'-oligoadenylate	47-67	ribonuclease L	Homo sapiens	32-39
22875977-5	2012	Similarly, direct activation of RNase L with a 2",5"-oligoadenylate resulted in p62(SQSTM1) degradation, LC3BI/LC3BII conversion, and appearance of autophagosomes.	2',5'-oligoadenylate	47-67	sequestosome 1	Homo sapiens	80-83
22875977-5	2012	Similarly, direct activation of RNase L with a 2",5"-oligoadenylate resulted in p62(SQSTM1) degradation, LC3BI/LC3BII conversion, and appearance of autophagosomes.	2',5'-oligoadenylate	47-67	sequestosome 1	Homo sapiens	84-90
22704621-5	2012	Ns2 cleaves 2",5"-oligoadenylate, the product of OAS, to prevent activation of the cellular endoribonuclease RNase L and consequently block viral RNA degradation.	2',5'-oligoadenylate	12-32	ribonuclease L (2', 5'-oligoisoadenylate synthetase-dependent)	Mus musculus	109-116
22497258-0	2012	Structure-activity relationships of 2",5"-oligoadenylate analogue modifications of prostate-specific membrane antigen (PSMA) antagonists.	2',5'-oligoadenylate	36-56	folate hydrolase 1	Homo sapiens	119-123
17912434-1	2007	We recently showed that therapy with 2"-5"-oligoadenylate (2-5A)-linked antisense against human telomerase RNA component (2-5A-anti-hTR) is a novel telomerase-targeting strategy against malignant gliomas.	2',5'-oligoadenylate	37-57	telomerase RNA component	Homo sapiens	132-135
22357208-1	2012	The interferon (IFN)-inducible, 2",5"-oligoadenylate (2-5A)-dependent ribonuclease L (RNase L) plays key role in antiviral defense of mammalian cells.	2',5'-oligoadenylate	32-52	interferon alpha 1	Homo sapiens	4-14
22357208-1	2012	The interferon (IFN)-inducible, 2",5"-oligoadenylate (2-5A)-dependent ribonuclease L (RNase L) plays key role in antiviral defense of mammalian cells.	2',5'-oligoadenylate	32-52	interferon alpha 1	Homo sapiens	16-19
22357208-1	2012	The interferon (IFN)-inducible, 2",5"-oligoadenylate (2-5A)-dependent ribonuclease L (RNase L) plays key role in antiviral defense of mammalian cells.	2',5'-oligoadenylate	32-52	ribonuclease L	Homo sapiens	70-84
22357208-1	2012	The interferon (IFN)-inducible, 2",5"-oligoadenylate (2-5A)-dependent ribonuclease L (RNase L) plays key role in antiviral defense of mammalian cells.	2',5'-oligoadenylate	32-52	ribonuclease L	Homo sapiens	86-93
18575592-1	2008	UNLABELLED: THE BACKGROUND: Ribonuclease L (RNASEL), encoding the 2"-5"-oligoadenylate (2-5A)-dependent RNase L, is a key enzyme in the interferon induced antiviral and anti-proliferate pathway.	2',5'-oligoadenylate	66-86	ribonuclease L	Homo sapiens	28-42
18575592-1	2008	UNLABELLED: THE BACKGROUND: Ribonuclease L (RNASEL), encoding the 2"-5"-oligoadenylate (2-5A)-dependent RNase L, is a key enzyme in the interferon induced antiviral and anti-proliferate pathway.	2',5'-oligoadenylate	66-86	ribonuclease L	Homo sapiens	44-50
18575592-1	2008	UNLABELLED: THE BACKGROUND: Ribonuclease L (RNASEL), encoding the 2"-5"-oligoadenylate (2-5A)-dependent RNase L, is a key enzyme in the interferon induced antiviral and anti-proliferate pathway.	2',5'-oligoadenylate	66-86	ribonuclease L	Homo sapiens	104-111
20691082-7	2010	In addition, cleavage and degradation of tumor nucleolin in antisense HSP70 oligos injection group was significantly higher than that in random oligos injection group.	2',5'-oligoadenylate	76-82	nucleolin	Homo sapiens	47-56
20691082-7	2010	In addition, cleavage and degradation of tumor nucleolin in antisense HSP70 oligos injection group was significantly higher than that in random oligos injection group.	2',5'-oligoadenylate	76-82	heat shock protein family A (Hsp70) member 4	Homo sapiens	70-75
20022497-0	2010	5"-O-dephosphorylated 2",5"-oligoadenylate (2-5A) with 8-methyladenosine at the 2"-terminus activates human RNase L.	2',5'-oligoadenylate	22-42	ribonuclease L	Homo sapiens	108-115
19749291-1	2009	The 2",5"-oligoadenylate (2-5A) system is an interferon (IFN)-regulated RNA decay pathway that provides innate immunity against viral infections.	2',5'-oligoadenylate	4-24	interferon alpha 1	Homo sapiens	45-55
19749291-1	2009	The 2",5"-oligoadenylate (2-5A) system is an interferon (IFN)-regulated RNA decay pathway that provides innate immunity against viral infections.	2',5'-oligoadenylate	4-24	interferon alpha 1	Homo sapiens	57-60
17912434-1	2007	We recently showed that therapy with 2"-5"-oligoadenylate (2-5A)-linked antisense against human telomerase RNA component (2-5A-anti-hTR) is a novel telomerase-targeting strategy against malignant gliomas.	2',5'-oligoadenylate	59-63	telomerase RNA component	Homo sapiens	132-135
17461764-9	2007	An extremely low concentration of cisplatin in addition to Ps-S-Oligos further up-regulated p53 activity, provoking massive apoptotic induction.	2',5'-oligoadenylate	64-70	tumor protein p53	Homo sapiens	92-95
17662075-6	2007	Extensive genetic analyses show that several gene products, e.g. 2"-5"-oligoadenylate (2-5 A)-dependent Rnase, macrophage scavenger receptor 1 and Toll-like receptor-4, influence the susceptibility of prostate cells to infectious agents.	2',5'-oligoadenylate	65-85	ribonuclease L	Homo sapiens	87-167
17535916-2	2007	dsRNA produced during viral infections activates IFN-inducible synthetases that produce 5"-phosphorylated, 2",5"-oligoadenylates (2-5A) from ATP.	2',5'-oligoadenylate	107-128	interferon alpha 1	Homo sapiens	49-52
17091337-1	2007	Interferons (IFNs) induce a 2",5"-oligoadenylate (2-5A)-dependent ribonuclease L (RNase L) following virus-infection of mammalian cells.	2',5'-oligoadenylate	28-48	ribonuclease L	Homo sapiens	66-80
17091337-1	2007	Interferons (IFNs) induce a 2",5"-oligoadenylate (2-5A)-dependent ribonuclease L (RNase L) following virus-infection of mammalian cells.	2',5'-oligoadenylate	28-48	ribonuclease L	Homo sapiens	82-89
17263642-1	2007	Two major interferon (IFN)-mediated antiviral defense enzymes are double-stranded (ds)RNA-dependent 2",5"-oligoadenylate (2-5A) synthetase (2-5OAS) and p68 kinase (PKR).	2',5'-oligoadenylate	100-120	interferon alpha 1	Homo sapiens	10-20
17301585-7	2007	RNase L analysis was performed by gel electrophoresis using a radiolabeled 2",5"-oligoadenylate trimer.	2',5'-oligoadenylate	75-102	ribonuclease L	Homo sapiens	0-7
17263642-1	2007	Two major interferon (IFN)-mediated antiviral defense enzymes are double-stranded (ds)RNA-dependent 2",5"-oligoadenylate (2-5A) synthetase (2-5OAS) and p68 kinase (PKR).	2',5'-oligoadenylate	100-120	interferon alpha 1	Homo sapiens	22-25
17263642-1	2007	Two major interferon (IFN)-mediated antiviral defense enzymes are double-stranded (ds)RNA-dependent 2",5"-oligoadenylate (2-5A) synthetase (2-5OAS) and p68 kinase (PKR).	2',5'-oligoadenylate	100-120	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	164-167
18369820-4	2007	By linking 2-5A to an antisense oligonucleotide, RNase L degrades the targeted RNA specifically and effectively.	2',5'-oligoadenylate	11-15	ribonuclease L	Homo sapiens	49-56
18029773-9	2007	Moreover, Protein X was phosphorylated during the activation of RNase L by treatment with cytotoxic agent, ECyd, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl) cytosine and 2-5A.	2',5'-oligoadenylate	169-173	ribonuclease L	Homo sapiens	64-71
18029780-0	2007	Synthesis of 2",5"-oligoadenylate analogs possessing a linker moiety in the place of the second adenosine and their ability to activate human RNase L.	2',5'-oligoadenylate	13-33	ribonuclease L	Homo sapiens	142-149
18029780-1	2007	This paper describes the synthesis of 2",5"-oligoadenylate analogs possessing a linker moiety in the place of the second adenosine and their ability to activate human RNase L.	2',5'-oligoadenylate	38-58	ribonuclease L	Homo sapiens	167-174
17150838-1	2006	RNase L is an endoribonuclease that requires 2"-5" oligoadenylate to cleave single-stranded RNA.	2',5'-oligoadenylate	45-65	ribonuclease L	Homo sapiens	0-7
16789752-1	2006	To determine the influence of methylene group insertion in the internucleotide linkage on the binding process of 2",5"-oligoadenylates to RNase L, a series of 2"-phosphonate-modified trimers and tetramers were synthesized from appropriate monomeric units and evaluated for their ability to bind to murine RNase L.	2',5'-oligoadenylate	113-134	ribonuclease L (2', 5'-oligoisoadenylate synthetase-dependent)	Mus musculus	138-145
17200614-2	2004	This is primarily brought about by the IFN-inducible 2",5"-oligoadenylate (2-5A)-cofactor dependent ribonuclease L (RNase L).	2',5'-oligoadenylate	53-73	interferon alpha 1	Homo sapiens	39-42
16203993-0	2005	A transcriptional signaling pathway in the IFN system mediated by 2"-5"-oligoadenylate activation of RNase L.	2',5'-oligoadenylate	66-86	interferon alpha 1	Homo sapiens	43-46
16203993-0	2005	A transcriptional signaling pathway in the IFN system mediated by 2"-5"-oligoadenylate activation of RNase L.	2',5'-oligoadenylate	66-86	ribonuclease L	Homo sapiens	101-108
15924878-0	2005	2",5"-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome.	2',5'-oligoadenylate	0-20	ribonuclease L	Homo sapiens	49-56
15604285-0	2004	HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2",5"-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.	2',5'-oligoadenylate	69-90	ribonuclease L	Homo sapiens	5-11
15604285-4	2004	Cells deficient in RNase L, but not the control cells, were highly resistant to apoptosis by the RNase L activator, 2",5"-oligoadenylate (2-5A).	2',5'-oligoadenylate	116-136	ribonuclease L	Homo sapiens	19-26
15604285-4	2004	Cells deficient in RNase L, but not the control cells, were highly resistant to apoptosis by the RNase L activator, 2",5"-oligoadenylate (2-5A).	2',5'-oligoadenylate	116-136	ribonuclease L	Homo sapiens	97-104
16241858-1	2005	2",5"-Oligoadenylate (2-5A)-dependent RNase L is a ubiquitous endoribonuclease of higher vertebrates that functions in the interferon (IFN) antiviral response by degrading both viral and cellular single-stranded RNA (ssRNA).	2',5'-oligoadenylate	0-20	ribonuclease L	Homo sapiens	38-45
16241858-1	2005	2",5"-Oligoadenylate (2-5A)-dependent RNase L is a ubiquitous endoribonuclease of higher vertebrates that functions in the interferon (IFN) antiviral response by degrading both viral and cellular single-stranded RNA (ssRNA).	2',5'-oligoadenylate	0-20	interferon alpha 1	Homo sapiens	123-133
16241858-1	2005	2",5"-Oligoadenylate (2-5A)-dependent RNase L is a ubiquitous endoribonuclease of higher vertebrates that functions in the interferon (IFN) antiviral response by degrading both viral and cellular single-stranded RNA (ssRNA).	2',5'-oligoadenylate	0-20	interferon alpha 1	Homo sapiens	135-138
15496827-9	2004	TER was significantly increased across TM cell monolayers grown in high glucose compared to those grown in normal medium (143+/-11% of control, p=0.001), which was reduced when cells were transfected with AS-FN oligos (109+/-7% of control, p=0.02) whereas cells transfected with random oligos showed no change.	2',5'-oligoadenylate	211-217	fibronectin 1	Homo sapiens	208-210
15357966-0	2004	Synthesis of 2",5"-oligoadenylate analogs containing an adenine acyclonucleoside and their ability to activate human RNase L.	2',5'-oligoadenylate	13-33	ribonuclease L	Homo sapiens	117-124
17200614-2	2004	This is primarily brought about by the IFN-inducible 2",5"-oligoadenylate (2-5A)-cofactor dependent ribonuclease L (RNase L).	2',5'-oligoadenylate	53-73	ribonuclease L	Homo sapiens	100-114
17200614-2	2004	This is primarily brought about by the IFN-inducible 2",5"-oligoadenylate (2-5A)-cofactor dependent ribonuclease L (RNase L).	2',5'-oligoadenylate	53-73	ribonuclease L	Homo sapiens	116-123
14583476-0	2003	Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2",5"-oligoadenylates.	2',5'-oligoadenylate	85-106	ribonuclease L	Homo sapiens	11-18
19621751-3	2004	The pre-incubation of isolated splenocytes and thymocytes with interferon inducers (cycloferone, mitogenic lectines and poly(I) x poly(C) caused the amplification of post-radiactive 2",5"-oligoadenylate accumulation and 2",5"-oligoadenylate-synthetase activity stimulation.	2',5'-oligoadenylate	182-202	2'-5' oligoadenylate synthetase 1A	Rattus norvegicus	220-251
14592484-0	2003	Synthesis of double-headed 2-5A-antisense chimeras and their ability to activate human RNase L.	2',5'-oligoadenylate	27-31	ribonuclease L	Homo sapiens	87-94
14592484-2	2003	The ability of the synthesized 2-5A antisense chimeras to activate RNase L was estimated by monitoring the cleavage of a target RNA by the activated RNase L.	2',5'-oligoadenylate	31-35	ribonuclease L	Homo sapiens	67-74
14592484-2	2003	The ability of the synthesized 2-5A antisense chimeras to activate RNase L was estimated by monitoring the cleavage of a target RNA by the activated RNase L.	2',5'-oligoadenylate	31-35	ribonuclease L	Homo sapiens	149-156
15063798-1	2004	Interferon-inducible ribonuclease L (RNase L) is a unique ankyrin-repeat containing endoribonuclease activated by 2",5"-oligoadenylate (2-5A) cofactor leading to RNA degradation and apoptosis during antiviral response in mammalian cells.	2',5'-oligoadenylate	114-134	ribonuclease L	Homo sapiens	21-35
15063798-1	2004	Interferon-inducible ribonuclease L (RNase L) is a unique ankyrin-repeat containing endoribonuclease activated by 2",5"-oligoadenylate (2-5A) cofactor leading to RNA degradation and apoptosis during antiviral response in mammalian cells.	2',5'-oligoadenylate	114-134	ribonuclease L	Homo sapiens	37-44
14761960-7	2004	ERalpha increased MPG acetylation, stabilized the binding of MPG with hypoxanthine-containing oligos, and enhanced MPG-catalyzed removal of hypoxanthine from DNA.	2',5'-oligoadenylate	94-100	estrogen receptor 1	Homo sapiens	0-7
14761960-7	2004	ERalpha increased MPG acetylation, stabilized the binding of MPG with hypoxanthine-containing oligos, and enhanced MPG-catalyzed removal of hypoxanthine from DNA.	2',5'-oligoadenylate	94-100	N-methylpurine DNA glycosylase	Homo sapiens	61-64
14761960-7	2004	ERalpha increased MPG acetylation, stabilized the binding of MPG with hypoxanthine-containing oligos, and enhanced MPG-catalyzed removal of hypoxanthine from DNA.	2',5'-oligoadenylate	94-100	N-methylpurine DNA glycosylase	Homo sapiens	61-64
11572597-7	2001	Two S-oligos were found to be effective in reducing the level of cox-2 protein selectively without any effect on the cox-1.	2',5'-oligoadenylate	6-12	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	65-70
12829380-8	2003	Administration of antisense oligonucleotides to Galpha(q/11) led to significant reductions in autoantibody levels, serum IgG levels, hematuria, and proteinuria compared to missense oligos.	2',5'-oligoadenylate	181-187	DNA segment, National Institute of Radiological Sciences, Japan-1	Mus musculus	48-60
12757397-4	2003	Incorporation of the hydroxyethyl group into the 2-5A tetramer and 2-5A-antisense chimera slightly reduced the abilities of their analogues to activate recombinant human RNase L, but the abilities of the 2-5A tetramer and the 2-5A-antisense chimera both with the hydroxyethyl group and 8-methyladenosine returned to 80 and 50% relative to those of the oligonucleotides without the hydroxyethyl group and 8-methyladenosine, respectively.	2',5'-oligoadenylate	49-53	ribonuclease L	Homo sapiens	170-177
12757397-4	2003	Incorporation of the hydroxyethyl group into the 2-5A tetramer and 2-5A-antisense chimera slightly reduced the abilities of their analogues to activate recombinant human RNase L, but the abilities of the 2-5A tetramer and the 2-5A-antisense chimera both with the hydroxyethyl group and 8-methyladenosine returned to 80 and 50% relative to those of the oligonucleotides without the hydroxyethyl group and 8-methyladenosine, respectively.	2',5'-oligoadenylate	67-71	ribonuclease L	Homo sapiens	170-177
12757397-4	2003	Incorporation of the hydroxyethyl group into the 2-5A tetramer and 2-5A-antisense chimera slightly reduced the abilities of their analogues to activate recombinant human RNase L, but the abilities of the 2-5A tetramer and the 2-5A-antisense chimera both with the hydroxyethyl group and 8-methyladenosine returned to 80 and 50% relative to those of the oligonucleotides without the hydroxyethyl group and 8-methyladenosine, respectively.	2',5'-oligoadenylate	67-71	ribonuclease L	Homo sapiens	170-177
12757397-4	2003	Incorporation of the hydroxyethyl group into the 2-5A tetramer and 2-5A-antisense chimera slightly reduced the abilities of their analogues to activate recombinant human RNase L, but the abilities of the 2-5A tetramer and the 2-5A-antisense chimera both with the hydroxyethyl group and 8-methyladenosine returned to 80 and 50% relative to those of the oligonucleotides without the hydroxyethyl group and 8-methyladenosine, respectively.	2',5'-oligoadenylate	67-71	ribonuclease L	Homo sapiens	170-177
14510381-0	2003	Synthesis of double-headed 2-5A-antisense chimeras and their ability to activate human RNase L.	2',5'-oligoadenylate	27-31	ribonuclease L	Homo sapiens	87-94
14510381-2	2003	The ability of the synthesized 2-5A antisense chimeras to activate RNase L was estimated by monitoring the cleavage of a target RNA by the activated RNase L.	2',5'-oligoadenylate	31-35	ribonuclease L	Homo sapiens	67-74
14510381-2	2003	The ability of the synthesized 2-5A antisense chimeras to activate RNase L was estimated by monitoring the cleavage of a target RNA by the activated RNase L.	2',5'-oligoadenylate	31-35	ribonuclease L	Homo sapiens	149-156
12034027-1	2002	A 2",5"-oligoadenylate (2-5A)-dependent 37-kDa form of RNase L has been reported in extracts of peripheral blood mononuclear cells (PBMC) from individuals with chronic fatigue syndrome (CFS).	2',5'-oligoadenylate	2-22	ribonuclease L	Homo sapiens	55-62
11799394-2	2002	Here we report that germline mutations in the gene encoding 2"-5"-oligoadenylate(2-5A)-dependent RNase L (RNASEL) segregate in prostate cancer families that show linkage to the HPC1 (hereditary prostate cancer 1) region at 1q24-25 (ref.	2',5'-oligoadenylate	60-80	ribonuclease L	Homo sapiens	106-112
12903097-4	2002	Incorporation of the hydroxyethyl group into the 2-5A tetramer and 2-5A-antisense chimera slightly reduced the abilities of their analogs to activate recombinant human RNase L, but the abilities of the 2-5A tetramer, 11, and the 2-5A-antisense chimera, 15, with the hydroxyethyl group and 1 returned to 80 and 50% relative to those of the un-modified oligonucleotides, 7 and 12, respectively.	2',5'-oligoadenylate	49-53	ribonuclease L	Homo sapiens	168-175
11705403-8	2001	The K(m,NAD) for Tpt1 is substrate dependent: K(m,NAD) is 10 microM with ligated tRNA, 200 microM with pApA(p)pA, and 600 microM with pApApA(p).	2',5'-oligoadenylate	134-140	tRNA 2'-phosphotransferase	Saccharomyces cerevisiae S288C	17-21
12887828-7	2003	GMSA and competition experiments demonstrated binding to both HNF4 and IE1.2 fragments could be competed with the cold specific oligonucleotides but not with the same amount of non-specific oligos nucleotides.	2',5'-oligoadenylate	190-196	hepatic nuclear factor 4, alpha	Mus musculus	62-66
12887828-7	2003	GMSA and competition experiments demonstrated binding to both HNF4 and IE1.2 fragments could be competed with the cold specific oligonucleotides but not with the same amount of non-specific oligos nucleotides.	2',5'-oligoadenylate	190-196	olfactory receptor family 13 subfamily A member 20	Mus musculus	71-76
11342638-7	2001	The IFN-gamma response can be blocked by 2",5"-oligoadenylate-linked antisense chimeras against PKR mRNA.	2',5'-oligoadenylate	41-61	interferon gamma	Homo sapiens	4-13
11472236-8	2001	Applications of 2-5A-antisense to particular targets such as HIV, PKR, chronic myelogenous leukemia, telomerase, and respiratory syncytical virus are described.	2',5'-oligoadenylate	16-20	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	66-69
11351264-1	2001	2",5"-Oligoadenylate (2-5A) linked to an antisense oligonucleotide against human telomerase RNA (2-5A-anti-hTR) is a novel therapeutic modality we have recently developed.	2',5'-oligoadenylate	0-20	telomerase RNA component	Homo sapiens	107-110
11351264-1	2001	2",5"-Oligoadenylate (2-5A) linked to an antisense oligonucleotide against human telomerase RNA (2-5A-anti-hTR) is a novel therapeutic modality we have recently developed.	2',5'-oligoadenylate	22-26	telomerase RNA component	Homo sapiens	107-110
11351264-5	2001	Six human malignant glioma cell lines with telomerase activity were treated with 0.5 microM 2-5A-anti-hTR and/or cisplatin (0, 0.1, 1, 5, 10, or 20 microg/ml) for three days, and cell viability was measured using the MTT colorimetric assay.	2',5'-oligoadenylate	92-96	telomerase RNA component	Homo sapiens	102-105
11342638-7	2001	The IFN-gamma response can be blocked by 2",5"-oligoadenylate-linked antisense chimeras against PKR mRNA.	2',5'-oligoadenylate	41-61	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	96-99
11320413-6	2001	The 2-5A antisense strategy relies on the recruitment and activation of RNase L at the site of targeted RNA sequence.	2',5'-oligoadenylate	4-8	ribonuclease L	Homo sapiens	72-79
11348873-7	2001	Electrophoretic mobility shift assay with use of radiolabeled oligo A showed a lyso-PC-inducible shift band, which was suppressed by excess amounts of unlabeled oligo A or an anti-Egr-1 antibody.	2',5'-oligoadenylate	62-69	early growth response 1	Bos taurus	180-185
11348873-7	2001	Electrophoretic mobility shift assay with use of radiolabeled oligo A showed a lyso-PC-inducible shift band, which was suppressed by excess amounts of unlabeled oligo A or an anti-Egr-1 antibody.	2',5'-oligoadenylate	161-168	early growth response 1	Bos taurus	180-185
11223987-3	2000	We have recently demonstrated that the treatment with a 19-mer antisense oligonucleotide against human telomerase RNA linked to a 2",5"-oligoadenylate (2-5A-anti-hTR) inhibited the growth of malignant glioma cells.	2',5'-oligoadenylate	130-150	telomerase RNA component	Homo sapiens	162-165
11586893-0	2001	Accelerating RNA decay through intervention of RNase L: alternative synthesis of composite 2",5"-oligoadenylate-antisense.	2',5'-oligoadenylate	91-111	ribonuclease L	Homo sapiens	47-54
10822370-6	2000	The 2-5A antisense strategy relies on the recruitment and activation of RNase L at the site of targeted RNA sequence.	2',5'-oligoadenylate	4-8	ribonuclease L	Homo sapiens	72-79
11152576-1	2000	The 2",5"-oligoadenylate (2-5A) system is an interferon (IFN)-regulated RNA decay pathway that provides innate immunity against viral infections.	2',5'-oligoadenylate	4-24	interferon alpha 1	Homo sapiens	45-55
11152576-1	2000	The 2",5"-oligoadenylate (2-5A) system is an interferon (IFN)-regulated RNA decay pathway that provides innate immunity against viral infections.	2',5'-oligoadenylate	4-24	interferon alpha 1	Homo sapiens	57-60
10926206-1	2000	The 2",5"-oligoadenylate (2-5A)/RNase L pathway is one of several enzymatic pathways induced by interferons (IFN).	2',5'-oligoadenylate	4-24	ribonuclease L	Homo sapiens	32-39
10637068-2	2000	To direct RNase L to an RNA target, 2-5A is attached to an antisense oligonucleotide (2-5A antisense).	2',5'-oligoadenylate	36-40	ribonuclease L	Homo sapiens	10-17
10637068-2	2000	To direct RNase L to an RNA target, 2-5A is attached to an antisense oligonucleotide (2-5A antisense).	2',5'-oligoadenylate	86-90	ribonuclease L	Homo sapiens	10-17
10637068-4	2000	Our objective is to investigate the effect of 2-5A antisense by targeting telomerase RNA (hTR) in the ovarian cancer cell line, HEY-1B.	2',5'-oligoadenylate	46-50	telomerase RNA component	Homo sapiens	90-93
10637068-13	2000	HEY1B cells treated with 2-5A antisense against hTR showed a decrease in telomerase activity and a profound induction of programmed cell death.	2',5'-oligoadenylate	25-29	telomerase RNA component	Homo sapiens	48-51
12903252-1	2000	The unique 2",5"-oligoadenylate (2-5A) acts as a potent inhibitor of translation in vertebrate cells through the activation of a constituent latent 2-5A-dependent endoribonuclease (RNase L).	2',5'-oligoadenylate	11-31	ribonuclease L	Homo sapiens	181-188
10524248-1	1999	Protein kinase C (PKC) is required for transcriptional induction of 2"-5"-oligoadenylate (2-5A) synthetases by interferon (IFN)-alpha.	2',5'-oligoadenylate	68-88	interferon alpha 1	Homo sapiens	111-133
9834240-0	1998	2",5"-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells.	2',5'-oligoadenylate	0-20	ribonuclease L	Homo sapiens	46-53
10230638-0	1999	Discrimination between ribonuclease H- and ribonuclease L-mediated RNA degradation by 2"-O-methylated 2-5A-antisense oligonucleotides.	2',5'-oligoadenylate	102-106	ribonuclease L	Homo sapiens	43-57
9671772-3	1998	Chemical conjugation of 2-5A to an antisense oligonucleotide can target the 2-5A-dependent RNase L to the antisense-specified RNA and effect its selective destruction.	2',5'-oligoadenylate	24-28	ribonuclease L	Homo sapiens	91-98
9681832-4	1998	2-5A antisense functions by activating the endoribonuclease, RNase L, resulting in the degradation of single stranded, targeted RNA.	2',5'-oligoadenylate	0-4	ribonuclease L	Homo sapiens	61-68
9660242-2	1998	Activated by 2",5"-oligoadenylate oligomers (2-5A), this enzyme controls the regulation of RNA stability in IFN-treated or virus-infected mammalian cells.	2',5'-oligoadenylate	13-33	interferon alpha 1	Homo sapiens	108-111
9735309-3	1998	Covalent linkage of 2-5A to antisense oligonucleotides permits recruitment of RNase L for enhancement of antisense action.	2',5'-oligoadenylate	20-24	ribonuclease L	Homo sapiens	78-85
9735309-5	1998	In addition, such assays will facilitate the screening of 2-5A-antisense congeners for exploration of the potential therapeutic applications of RNase L.	2',5'-oligoadenylate	58-62	ribonuclease L	Homo sapiens	144-151
9660177-1	1998	The interferon-(IFN)-inducible 2",5"-oligoadenylate (2-5A)/endoribonuclease L (RNase L) pathway plays a major role in the antiviral and antiproliferative effects of IFN.	2',5'-oligoadenylate	31-51	interferon alpha 1	Homo sapiens	4-20
9660177-1	1998	The interferon-(IFN)-inducible 2",5"-oligoadenylate (2-5A)/endoribonuclease L (RNase L) pathway plays a major role in the antiviral and antiproliferative effects of IFN.	2',5'-oligoadenylate	31-51	ribonuclease L	Homo sapiens	79-86
9660177-1	1998	The interferon-(IFN)-inducible 2",5"-oligoadenylate (2-5A)/endoribonuclease L (RNase L) pathway plays a major role in the antiviral and antiproliferative effects of IFN.	2',5'-oligoadenylate	31-51	interferon alpha 1	Homo sapiens	16-19
9875401-0	1998	Targeting RNase L to human immunodeficiency virus RNA with 2-5A-antisense.	2',5'-oligoadenylate	59-63	ribonuclease L	Homo sapiens	10-17
9012860-1	1996	Composite nucleic acids, known as 2-5A antisense chimeras, cause the 2-5A-dependent ribonuclease (RNase L) to catalyze the specific cleavage of RNA in cell free systems and in intact cells.	2',5'-oligoadenylate	34-38	ribonuclease L	Homo sapiens	98-105
9554886-4	1998	2-5A-Iso-antisense was able to effect the degradation of a synthetic nontargeted substrate, [5"-32P]pC11U2C7, and two targeted RNAs, PKR and BCR mRNAs, in a cell-free system containing purified recombinant human 2-5A-dependent RNase L. These results demonstrated that the novel structural modification represented by 2-5A-iso-antisense provided a stabilized biologically active formulation of the 2-5A-antisense strategy.	2',5'-oligoadenylate	0-4	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	133-136
9260891-1	1997	Induction of the p40/46 and p69/71 isoforms of the 2",5"-oligoadenylate (2-5A) synthetase by interferon-alpha (IFN-alpha) is variable among six different Burkitt lymphoma cell lines with Ramos cells expressing among the highest levels of these enzymes.	2',5'-oligoadenylate	51-71	islet cell autoantigen 1	Homo sapiens	28-31
9260891-1	1997	Induction of the p40/46 and p69/71 isoforms of the 2",5"-oligoadenylate (2-5A) synthetase by interferon-alpha (IFN-alpha) is variable among six different Burkitt lymphoma cell lines with Ramos cells expressing among the highest levels of these enzymes.	2',5'-oligoadenylate	51-71	interferon alpha 1	Homo sapiens	111-120
9235909-0	1997	Activation of RNase L by 2",5"-oligoadenylates.	2',5'-oligoadenylate	25-46	ribonuclease L	Homo sapiens	14-21
9235910-0	1997	Activation of RNase L by 2",5"-oligoadenylates.	2',5'-oligoadenylate	25-46	ribonuclease L	Homo sapiens	14-21
9056678-10	1997	We conclude that the oligo-A-containing region of the 3" UTR of CEA (204 bp beginning at nucleotide 24229) does not play a substantial role in the regulation of CEA expression.	2',5'-oligoadenylate	21-28	CEA cell adhesion molecule 3	Homo sapiens	64-67
9027590-5	1997	Out of 14 oligos tested, inhibition of activation of P1 and/or P3 was observed with four antisense oligonucleotides corresponding to looped regions in the putative 7SK secondary structure.	2',5'-oligoadenylate	10-16	solute carrier family 10 (sodium/bile acid cotransporter family), member 3	Mus musculus	53-65
9525594-1	1998	The 2",5"-oligoadenylate (2-5A) system is an RNA degradation pathway which plays an important role in the antipicornavirus effects of interferon (IFN).	2',5'-oligoadenylate	4-24	interferon alpha 1	Homo sapiens	134-150
9111293-4	1997	When the biological activity of these new chimeric oligonucleotides was compared to that of the parent chimera, 2-5A-aPKR, for their ability to effect target PKR RNA cleavage in a cell-free and in an intact cell assay, it was determined that there was a close correlation between the activity of 2-5A-antisense chimeras and their affinity (Tm) for a targeted nucleic acid.	2',5'-oligoadenylate	112-116	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	118-121
9111293-5	1997	In addition, there was also a close correlation between activity of the 2-5A-antisense chimeras and their ability to activate the 2-5A-dependent RNase L.	2',5'-oligoadenylate	72-76	ribonuclease L	Homo sapiens	145-152
8626728-0	1996	Stoichiometry of 2",5"-oligoadenylate-induced dimerization of ribonuclease L.	2',5'-oligoadenylate	17-37	ribonuclease L	Homo sapiens	62-76
7622300-8	1995	Accordingly, 2,5 OAS enzymatic activity, virtually undetectable in untreated LAN-5 cells, increased up to 132 pmol oligoadenylate/micrograms protein/hr after 48 hr of treatment, then slowly decreased, remaining detectable up to 96 hr.	2',5'-oligoadenylate	115-129	SPARC related modular calcium binding 1	Homo sapiens	17-20
8023698-3	1993	FCS was also found to be a dose-dependent enhancer of the IFN-gamma-induced 2",5"-oligoadenylate (2-5A) synthetase production.	2',5'-oligoadenylate	76-96	interferon gamma	Homo sapiens	58-67
7797490-1	1995	2-5A antisense (2-5A-AS) molecules are chimeric oligonucleotides that cause 2-5A-dependent RNase (RNase L) to catalyze the selective cleavage of RNA in human cells.	2',5'-oligoadenylate	0-4	ribonuclease L	Homo sapiens	98-105
7797490-2	1995	These composite nucleic acids consist of a 5"-monophosphorylated, 2",5"-linked oligoadenylate known as 2-5A (an activator of RNase L) covalently attached to antisense 3",5"-oligodeoxyribonucleotides.	2',5'-oligoadenylate	103-107	ribonuclease L	Homo sapiens	125-132
7890727-0	1995	Inhibition of HIV-1 replication and activation of RNase L by phosphorothioate/phosphodiester 2",5"-oligoadenylate derivatives.	2',5'-oligoadenylate	93-113	ribonuclease L (2', 5'-oligoisoadenylate synthetase-dependent)	Mus musculus	50-57
7890727-1	1995	2",5"-Oligoadenylate (2-5A) derivatives have been designed to act distal to the human immunodeficiency virus-1 (HIV-1)-induced blockade in the 2-5A synthetase/RNase L antiviral pathway.	2',5'-oligoadenylate	0-20	ribonuclease L (2', 5'-oligoisoadenylate synthetase-dependent)	Mus musculus	159-166
7648430-1	1995	The 2",5"-oligoadenylate (2-5A) synthetase pathway, induced by interferon-alpha (IFN-alpha), has been shown to be responsible for the antiviral action of IFN-alpha against some viruses.	2',5'-oligoadenylate	4-24	interferon alpha-2	Chlorocebus sabaeus	63-79
7648430-1	1995	The 2",5"-oligoadenylate (2-5A) synthetase pathway, induced by interferon-alpha (IFN-alpha), has been shown to be responsible for the antiviral action of IFN-alpha against some viruses.	2',5'-oligoadenylate	4-24	interferon alpha-2	Chlorocebus sabaeus	81-90
7648430-1	1995	The 2",5"-oligoadenylate (2-5A) synthetase pathway, induced by interferon-alpha (IFN-alpha), has been shown to be responsible for the antiviral action of IFN-alpha against some viruses.	2',5'-oligoadenylate	4-24	interferon alpha-2	Chlorocebus sabaeus	154-163
7914032-0	1994	Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras.	2',5'-oligoadenylate	76-80	nuclear factor kappa B subunit 1	Homo sapiens	12-22
34372695-1	2021	The 2",5"-oligoadenylate (2-5A)-dependent endoribonuclease, RNase L, is a principal mediator of the interferon (IFN) antiviral response.	2',5'-oligoadenylate	4-24	ribonuclease L	Homo sapiens	60-67
7685081-1	1993	In continued studies to elucidate the requirements for binding to and activation of the 2",5"-oligoadenylate (2-5A) dependent endoribonuclease (RNase L), four 2-5A trimer analogs were examined to evaluate the effect of chirality of phosphorothioate substitution on biological activity.	2',5'-oligoadenylate	88-108	ribonuclease L	Homo sapiens	144-151
2140395-7	1990	Furthermore, incubation of EFC-2 cells for 72 h with either rIFN-alpha A or rIFN-beta ser resulted in an increase in 2",5"-oligoadenylate (2-5A) synthetase activity 5-fold with rIFN-alpha A and 50-fold with rIFN-beta ser.	2',5'-oligoadenylate	117-137	interferon beta 1	Rattus norvegicus	76-85
2140395-7	1990	Furthermore, incubation of EFC-2 cells for 72 h with either rIFN-alpha A or rIFN-beta ser resulted in an increase in 2",5"-oligoadenylate (2-5A) synthetase activity 5-fold with rIFN-alpha A and 50-fold with rIFN-beta ser.	2',5'-oligoadenylate	117-137	interferon beta 1	Rattus norvegicus	207-216
2090799-0	1990	2",5"-Oligoadenylate (2-5A) binding protein (RNase L) changes in AIDS and mammalian cells/tissues.	2',5'-oligoadenylate	0-20	ribonuclease L	Homo sapiens	45-52
8471593-3	1993	IFN-induced products of gene regulation assessed were beta 2-microglobulin, neopterin, and tryptophan in serum and 2",5"-oligoadenylate (2-5A) synthetase activity in peripheral blood mononuclear cells.	2',5'-oligoadenylate	115-135	interferon alpha 1	Homo sapiens	0-3
1289408-2	1992	These IFN-induced metabolites, beta 2-microglobulin, and neopterin in serum, and 2",5"-oligoadenylate (2-5A) synthetase in peripheral blood mononuclear cells, are more sensitive to the presence of IFN than bioassay of IFN in serum.	2',5'-oligoadenylate	81-101	interferon alpha 1	Homo sapiens	197-200
1289408-2	1992	These IFN-induced metabolites, beta 2-microglobulin, and neopterin in serum, and 2",5"-oligoadenylate (2-5A) synthetase in peripheral blood mononuclear cells, are more sensitive to the presence of IFN than bioassay of IFN in serum.	2',5'-oligoadenylate	81-101	interferon alpha 1	Homo sapiens	197-200
1379287-1	1992	In tertiary MEF undergoing cell cycle progression, autocrine interferon (IFN) is released and constitutive levels of 2",5"-oligoadenylate (2-5A) synthetase activity, low through the cell cycle, surge into a peak within S phase.	2',5'-oligoadenylate	117-137	E74 like ETS transcription factor 4	Homo sapiens	12-15
1379287-1	1992	In tertiary MEF undergoing cell cycle progression, autocrine interferon (IFN) is released and constitutive levels of 2",5"-oligoadenylate (2-5A) synthetase activity, low through the cell cycle, surge into a peak within S phase.	2',5'-oligoadenylate	117-137	interferon alpha 1	Homo sapiens	73-76
1714563-4	1991	Both binding and activation of mouse liver 2-5A dependent ribonuclease (RNase L) by the various 8-methyladenosine-substituted 2-5A analogues were examined.	2',5'-oligoadenylate	43-47	ribonuclease L (2', 5'-oligoisoadenylate synthetase-dependent)	Mus musculus	72-79
1690591-1	1990	Vasoactive Intestinal Peptide (VIP) is able at the concentration 10 to 100 nM to induce in HT-29 cells 2"5" oligoadenylate (2"5" A) synthetase activity.	2',5'-oligoadenylate	103-122	vasoactive intestinal peptide	Homo sapiens	0-29
1690591-1	1990	Vasoactive Intestinal Peptide (VIP) is able at the concentration 10 to 100 nM to induce in HT-29 cells 2"5" oligoadenylate (2"5" A) synthetase activity.	2',5'-oligoadenylate	103-122	vasoactive intestinal peptide	Homo sapiens	31-34
34372695-14	2021	These viral and host enzymes, which we refer to as 2",5"-PEs, specifically degrade 2",5"-oligoadenylate activators of the antiviral enzyme RNase L.	2',5'-oligoadenylate	83-103	ribonuclease L	Homo sapiens	139-146
34145065-2	2021	Oligoadenylate synthetase 1 is a type I interferon-induced, intracellular double-stranded RNA (dsRNA) sensor that generates 2"-5"-oligoadenylate to activate ribonuclease L (RNase L) as a means of antiviral defense.	2',5'-oligoadenylate	124-144	ribonuclease L	Homo sapiens	157-171
34145065-2	2021	Oligoadenylate synthetase 1 is a type I interferon-induced, intracellular double-stranded RNA (dsRNA) sensor that generates 2"-5"-oligoadenylate to activate ribonuclease L (RNase L) as a means of antiviral defense.	2',5'-oligoadenylate	124-144	ribonuclease L	Homo sapiens	173-180
35575378-4	2022	In this study, we developed a microscale thermophoresis-based assay to probe the interactions between PABP and oligoadenylate analogs containing different chemical modifications.	2',5'-oligoadenylate	111-125	poly(A) binding protein cytoplasmic 1	Homo sapiens	102-106
2538838-1	1989	Treatment of quiescent BALB/c mouse 3T3 cells with murine interferon alpha/beta (IFN-alpha/beta) (1000 units/ml) leads to the appearance at 4 hr of 1.7-kilobase 2",5"-oligoadenylate (2",5"-OAS)mRNA as detected by Northern blot analysis.	2',5'-oligoadenylate	161-181	interferon alpha B	Mus musculus	58-79
35153131-0	2022	Corrigendum to "5"-Phosphonate modified oligoadenylates as potent activators of human RNase L" (Bioorg.	2',5'-oligoadenylate	40-55	ribonuclease L	Homo sapiens	86-94
2480249-2	1989	The poly(rI) poly(rC)-induced inhibition of the enzymatic activity correlates with the observed increase of endogenous 2",5"-oligoadenylate cores which were reported to be potent inhibitors of ADPRP in vitro.	2',5'-oligoadenylate	119-139	poly (ADP-ribose) polymerase family, member 1	Mus musculus	193-198
2538838-1	1989	Treatment of quiescent BALB/c mouse 3T3 cells with murine interferon alpha/beta (IFN-alpha/beta) (1000 units/ml) leads to the appearance at 4 hr of 1.7-kilobase 2",5"-oligoadenylate (2",5"-OAS)mRNA as detected by Northern blot analysis.	2',5'-oligoadenylate	161-181	interferon alpha	Mus musculus	81-90
2466091-1	1988	In tertiary MEF undergoing cell cycle progression, autocrine interferon (IFN) is released and constitutive levels of 2",5"-oligoadenylate (2-5A) synthetase activity, low through the cell cycle, surge into a peak within S phase.	2',5'-oligoadenylate	117-137	E74 like ETS transcription factor 4	Homo sapiens	12-15
2472992-1	1989	The effect of retinoic acid (RA) on the level of interferon (IFN)-induced 2-5 oligoadenylate (2-5A) synthetase activity was examined in human histiocytic lymphoma U937 cells and WISH cells** in order to ascertain the role of this polymerase in interaction between IFNs and RA.	2',5'-oligoadenylate	74-92	interferon alpha 1	Homo sapiens	61-64
2533880-3	1989	The IFN-alpha 2 induces the activity of the 2"5" oligoadenylate (2"5" A) synthetase activity in these cells and partly inhibits their growth.	2',5'-oligoadenylate	44-63	interferon alpha 2	Homo sapiens	4-15
2523019-0	1989	Interferon and (2"-5")oligoadenylate enhance the expression of low affinity receptors for IgE (Fc epsilon R2/CD23) on the human monoblast cell line U937.	2',5'-oligoadenylate	15-36	Fc epsilon receptor II	Homo sapiens	109-113
2523019-2	1989	Alpha interferon (IFN-alpha) and its intracellular mediator, (2"-5")oligoadenylate (2, 5-A), induced Fc epsilon R2/CD23 expression on U937 with no significant increase of the Fc epsilon R2/CD23 mRNA.	2',5'-oligoadenylate	61-82	interferon alpha 1	Homo sapiens	0-27
2523019-2	1989	Alpha interferon (IFN-alpha) and its intracellular mediator, (2"-5")oligoadenylate (2, 5-A), induced Fc epsilon R2/CD23 expression on U937 with no significant increase of the Fc epsilon R2/CD23 mRNA.	2',5'-oligoadenylate	61-82	Fc epsilon receptor II	Homo sapiens	115-119
2523019-2	1989	Alpha interferon (IFN-alpha) and its intracellular mediator, (2"-5")oligoadenylate (2, 5-A), induced Fc epsilon R2/CD23 expression on U937 with no significant increase of the Fc epsilon R2/CD23 mRNA.	2',5'-oligoadenylate	61-82	Fc epsilon receptor II	Homo sapiens	189-193
2466091-1	1988	In tertiary MEF undergoing cell cycle progression, autocrine interferon (IFN) is released and constitutive levels of 2",5"-oligoadenylate (2-5A) synthetase activity, low through the cell cycle, surge into a peak within S phase.	2',5'-oligoadenylate	117-137	interferon alpha 1	Homo sapiens	73-76
2850448-1	1988	Pretreatment of mouse embryo fibroblasts (MEF) with recombinant murine interferon-beta (rMuIFN-beta) induced a high level of intracellular 2",5"-oligoadenylate (2-5A) synthetase activity.	2',5'-oligoadenylate	139-159	interferon beta 1, fibroblast	Mus musculus	71-86
2841470-7	1988	However, the level of RNase L, as determined by binding and cross-linking of a radiolabeled 2"-5"-oligoadenylate derivative, was much lower in RK6 cells than in RK8 cells.	2',5'-oligoadenylate	92-112	ribonuclease L	Homo sapiens	22-29
2987667-7	1985	The data presented suggest the involvement of two different mechanisms in regulation of 2"-phosphodiesterase activity: cAMP-dependent phosphorylation and induction of 2"-phosphodiesterase by 2",5"-oligoadenylate.	2',5'-oligoadenylate	191-211	phosphodiesterase 12	Mus musculus	88-108
2459906-1	1987	The effect of in vivo administered interferon-alpha (IFN-alpha) on 2-5-oligoadenylate (A) synthetase activity of peripheral blood mononuclear cells (PBMC) was compared in patients with hairy cell leukemia and renal cell cancer.	2',5'-oligoadenylate	67-85	interferon alpha 1	Homo sapiens	53-62
3585079-1	1987	Treatment of chronic hepatitis B (CHB) with human leukocyte interferon (IFN-alpha) was studied in terms of increase of 2",5"-oligoadenylate (2-5A) synthetase activity in peripheral blood lymphocytes (PBL) after IFN-alpha administration.	2',5'-oligoadenylate	119-139	interferon alpha 1	Homo sapiens	50-81
3585079-1	1987	Treatment of chronic hepatitis B (CHB) with human leukocyte interferon (IFN-alpha) was studied in terms of increase of 2",5"-oligoadenylate (2-5A) synthetase activity in peripheral blood lymphocytes (PBL) after IFN-alpha administration.	2',5'-oligoadenylate	119-139	interferon alpha 1	Homo sapiens	72-81
2429152-0	1986	RNase L, a (2"-5")-oligoadenylate-dependent endoribonuclease: assays and purification of the enzyme; cross-linking to a (2"-5")-oligoadenylate derivative.	2',5'-oligoadenylate	11-33	ribonuclease L	Homo sapiens	0-7
3872657-4	1985	On the other hand, the level of 2"-phosphodiesterase, which is also induced by interferon and degrades 2",5"-oligoadenylate, showed no significant change after dAdo treatment.	2',5'-oligoadenylate	103-123	phosphodiesterase 12	Homo sapiens	32-52
3036812-3	1987	A 2"-phosphodiesterase that degrades 2",5"-oligoadenylates was purified 1500-fold from a low speed homogenate of bovine spleen by precipitation at pH 5.2, ammonium sulfate fractionation, differential ultrafiltration, and successive chromatography on DEAE-Sephacel, hydroxylapatite, and a fast protein liquid chromatography Mono P column.	2',5'-oligoadenylate	43-58	phosphodiesterase 12	Bos taurus	2-22
3743655-4	1986	These results show that NGF modulates the activity of (2"-5")oligo(A) enzymes and intracellular concentration of 2"-5" A during the neural differentiation of PC12 cells.	2',5'-oligoadenylate	113-120	nerve growth factor	Rattus norvegicus	24-27
4000113-4	1985	The presence of several pH-optima for 2"-phosphodiesterase activity in L-cells and changes of the level of this activity depending on the growth stage of cells and time of their interferon treatment indicate the complicated character of the regulation of 2"-5"-oligoadenylate"s concentration and localization.	2',5'-oligoadenylate	255-275	phosphodiesterase 12	Mus musculus	38-58
2987667-7	1985	The data presented suggest the involvement of two different mechanisms in regulation of 2"-phosphodiesterase activity: cAMP-dependent phosphorylation and induction of 2"-phosphodiesterase by 2",5"-oligoadenylate.	2',5'-oligoadenylate	191-211	phosphodiesterase 12	Mus musculus	167-187
6189584-12	1983	The associated changes in the (2",5")oligoadenylate [(2",5")oligo(A)] pathway produced by IFN-beta and IFL-alpha A were measured under growth-inhibitory conditions.	2',5'-oligoadenylate	30-51	interferon beta 1	Homo sapiens	90-98
32678884-2	2020	dsRNA binding induces allosteric structural changes in OAS1 that reorganize its catalytic center to promote synthesis of 2"-5"-oligoadenylate and thus activation of endoribonuclease L. Specific RNA sequences and structural motifs can also enhance activation of OAS1 through currently undefined mechanisms.	2',5'-oligoadenylate	121-141	2'-5'-oligoadenylate synthetase 1	Homo sapiens	55-59
6163628-5	1981	The mitogenic stimulus produced by the lectin enhances, in lymphocytes, the level of the 2"-phosphodiesterase which degrades (2"-5")oligo(adenylate).	2',5'-oligoadenylate	125-148	phosphodiesterase 12	Mus musculus	89-109
222045-0	1979	Nuclease activation by double-stranded RNA and by 2",5"-oligoadenylate in extracts of interferon-treated chick cells.	2',5'-oligoadenylate	50-70	DNA cross-link repair 1C	Gallus gallus	0-8
32678884-2	2020	dsRNA binding induces allosteric structural changes in OAS1 that reorganize its catalytic center to promote synthesis of 2"-5"-oligoadenylate and thus activation of endoribonuclease L. Specific RNA sequences and structural motifs can also enhance activation of OAS1 through currently undefined mechanisms.	2',5'-oligoadenylate	121-141	2'-5'-oligoadenylate synthetase 1	Homo sapiens	261-265
32413313-2	2020	Upon binding dsRNA, OAS undergoes a conformational change and is activated to polymerize ATP into 2"-5"-oligoadenylate chains.	2',5'-oligoadenylate	98-118	SPARC related modular calcium binding 1	Homo sapiens	20-23
32413313-4	2020	In addition, oligomerization of OAS isozymes, potentially OAS1 and OAS2, is hypothesized to be important for 2"-5"-oligoadenylate chain building.	2',5'-oligoadenylate	109-129	SPARC related modular calcium binding 1	Homo sapiens	32-35
32413313-4	2020	In addition, oligomerization of OAS isozymes, potentially OAS1 and OAS2, is hypothesized to be important for 2"-5"-oligoadenylate chain building.	2',5'-oligoadenylate	109-129	2'-5'-oligoadenylate synthetase 1	Homo sapiens	58-62
32413313-4	2020	In addition, oligomerization of OAS isozymes, potentially OAS1 and OAS2, is hypothesized to be important for 2"-5"-oligoadenylate chain building.	2',5'-oligoadenylate	109-129	2'-5'-oligoadenylate synthetase 2	Homo sapiens	67-71
32325933-8	2020	PPRV replication in goat PBMCs significantly increased the expression of phosphodiesterase 12 (PDE12), a 2",5"-oligoadenylate degrading enzyme that contributes to the reduced modulation of interferon-regulated gene targets.	2',5'-oligoadenylate	105-125	phosphodiesterase 12	Homo sapiens	73-93
32325933-8	2020	PPRV replication in goat PBMCs significantly increased the expression of phosphodiesterase 12 (PDE12), a 2",5"-oligoadenylate degrading enzyme that contributes to the reduced modulation of interferon-regulated gene targets.	2',5'-oligoadenylate	105-125	phosphodiesterase 12	Homo sapiens	95-100